| James Torsney O.d. P.c. | |
| 1708 Main St, Tyndall, South Dakota 57066 | |
| (605) 589-3406 |
| Name | James Torsney O.d. P.c. |
|---|---|
| Organization Name | James Torsney O.d. P.c. |
| Location | 1708 Main St, Tyndall, South Dakota 57066 |
| Type | Supplier |
| Phone | (605) 589-3406 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The international AIDS conference in Washington has already made two points clear. There is no prospect that scientists will any time soon find the ultimate solutions to the AIDS epidemic, namely a vaccine that would prevent infection with the AIDS virus or a "cure" for people already infected with the virus.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
As of 31 March 2004, WHO has received reports of 43 cases and 7 deaths in the Central African Republic.
The Regenstrief Institute and Merck, known as MSD outside the United States and Canada, have signed a five-year agreement to collaborate on a range of projects that will use clinical data to inform personalized delivery of health care.
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
› Verified 5 days ago
News Archive
The international AIDS conference in Washington has already made two points clear. There is no prospect that scientists will any time soon find the ultimate solutions to the AIDS epidemic, namely a vaccine that would prevent infection with the AIDS virus or a "cure" for people already infected with the virus.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
As of 31 March 2004, WHO has received reports of 43 cases and 7 deaths in the Central African Republic.
The Regenstrief Institute and Merck, known as MSD outside the United States and Canada, have signed a five-year agreement to collaborate on a range of projects that will use clinical data to inform personalized delivery of health care.
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
› Verified 5 days ago
Bon Homme Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 410 West 16th Avenue, Tyndall, South Dakota 57066 Phone: (605) 589-2218 | |
James Torsney O.d. P.c. Type: Medicare Supplier Location: 1708 Main St, Tyndall, South Dakota 57066 Phone: (605) 589-3406 |